Peter is a partner and the president of RTW. In addition to his broad management and oversight of the firm, Peter has retained his role as head of Asset Development and Financing (ADF). One of ADF’s primary responsibilities is the creation and incubation of RTW-founded companies.
Peter also serves as founding CEO and board member of RTW’s incubated companies, building their management teams, pipelines, and drug development capabilities with the goal of creating the next generation of leading biotech firms capable of bringing life-saving medicines to patients. He currently serves on the board of directors for both Ji Xing Pharmaceuticals and Yarrow Biotechnologies, which were founded by RTW under his leadership.
Prior to joining RTW, Peter worked at Flagship Pioneering in Cambridge as a member of the innovation team. In this role he led the creation of four Flagship companies, including Harbinger Health, and served as the founding CEO of each of them.
Biotech entrepreneurism is central to the unprecedented biological innovation revolutionizing medicine. It’s a thrill to come to the office each day and work with colleagues as talented and entrepreneurial as they are at RTW. Together, we seek to create world class biotech companies – from the ground up – capable of taking on the worst diseases.
Peter previously worked at Genentech in Business Development, where he helped build the company’s pipeline through partnering. Peter led multiple transactions for Genentech, including the company’s collaboration with BioNTech to develop mRNA-based personalized cancer vaccines. He has also worked at Memorial Sloan-Kettering; Carigent Therapeutics, which he co-founded; and General Electric as a chemist.
Peter received a PhD in bioengineering from Yale University, where he subsequently was a Brown-Coxe Postdoctoral Fellow, and his BS in biochemistry from Indiana University.